Announcements
- Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications
- Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
- Monthly information on share capital and company voting rights
- Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
- Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
- Cellectis obtient la désignation de médicament orphelin pour son produit CAR T allogénique UCART22 pour les patients atteints de leucémie lymphoblastique aiguë
- Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
- L’ Assemblée Générale Mixte de Cellectis se tiendra le 28 juin 2024
- Cellectis publie ses résultats financiers du premier trimestre 2024
- Cellectis Reports Financial Results for First Quarter 2024
More ▼
Key statistics
As of last trade Cellectis SA (ZVAA:DUS) traded at 2.22, 1.83% above its 52-week low of 2.18, set on Mar 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.22 |
---|---|
High | 2.22 |
Low | 2.22 |
Bid | 2.12 |
Offer | 2.14 |
Previous close | 2.30 |
Average volume | 0.00 |
---|---|
Shares outstanding | 71.75m |
Free float | 65.01m |
P/E (TTM) | -- |
Market cap | 185.39m USD |
EPS (TTM) | -1.93 USD |
Data delayed at least 15 minutes, as of Jun 13 2024 07:12 BST.
More ▼